GlassScriptPhysician profile
Carlos Mata
NPI 1891986089
$15,417.82
in general payments reported to CMS, 2019-2025
19 companies · $2,817 in 2025
The $2,817 reported for 2025 was more than what 88% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,221 · 2020: $784 · 2021: $4,245 · 2022: $1,871 · 2023: $424 · 2024: $1,056 · 2025: $2,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,186 · Travel and Lodging: $1,024 · Gift: $87.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,186.16 |
| Travel and Lodging | $1,024.29 |
| Gift | $87.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,865.96 | 2019-2022 | |
| Motiva USA, LLC | $2,156.68 | 2025 | |
| Sientra, INC. | $1,883.55 | 2019-2022 | |
| Apyx Medical Corporation | $1,689.95 | 2019-2020 | |
| Mentor Worldwide LLC | $1,388.41 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer, Mentor Cpx 2 Breast Tissue Expander, Mentor Siltex Round Spectrum |
| Solta Medical, A Division of Bausch Health US, LLC | $976.10 | 2019-2024 | Clear+Brilliant |
| Merz North America, INC. | $847.16 | 2019-2022 | |
| Abbvie INC. | $728.58 | 2023-2025 | |
| Bard Peripheral Vascular, INC. | $538.09 | 2021 | |
| Galderma Laboratories, L.P. | $376.60 | 2019-2024 | |
| Davol INC. | $276.57 | 2021-2025 | Phasix Mesh |
| Tela Bio, INC. | $182.59 | 2023-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Innovation Technologies INC | $155.19 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $153.07 | 2019 | |
| Organogenesis INC. | $80.49 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $55.82 | 2025 | |
| Acelrx Pharmaceuticals, INC. | $25.53 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $20.11 | 2023 | Seglentis |
| Arteriocyte Medical Systems, INC. | $17.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Mata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.